The new probe provides doctors with multiple fields of view simultaneously, addressing the shortcomings of traditional endoscopes — and potentially preventing more instances of colon cancer.
Inventors at the University of Arizona have formed a startup, Omniscient LLC, and licensed a technology from the University through Tech Launch Arizona, the UA office that commercializes inventions stemming from research. Omniscient will commercialize a new endoscopic device that provides views that are not possible with current endoscopes.
The new probe provides doctors with multiple fields of view simultaneously to address the shortcomings of traditional endoscopes. The invention provides a simultaneous forward and 360-degree rearview in a single display. In the colon, it permits doctors to see forward and backward at the same time and see behind approximately 100 folds in a typical colon. The result is an imaging system that allows growths that are normally not seen by traditional forward-viewing endoscopes to be detected and removed, identifying more pre-cancerous polyps — and preventing many more cancers than conventional endoscopes.
Colonoscopy is the preferred procedure for colon cancer screening. It is estimated that more than 14 million colonoscopies are performed in the U.S. each year, at a cost of $24 billion. Studies have shown that 25 to 40 percent of pre-cancerous polyps are missed during a colonoscopy; more than 70 percent of the missed polyps are hidden behind folds in the colon.
Banerjee has spent most of his academic life trying to find optical techniques of seeing lesions in the gastrointestinal tract that are “invisible” to the human eye because they are flat and have the same color as the surrounding normal tissue. But there is another, more fundamental, problem: not being able to see the entire colon.
Banerjee and Liang estimate that a standard endoscope sees about 80 percent of the colon, leaving the rest unexamined. A “normal” colonoscopy may not be as normal as is commonly believed, and missed lesions can lead to unexpected cancers. This is now widely recognized, and benchmarks for polyp detection rates have developed, for individual physicians to monitor. Soon, reimbursement for colonoscopy, as well as patient referral, will be impacted by such metrics. Therefore, the commercialization of this invention could not have been timed better.
“We are using instruments that evolved out of the telescope to look forwards,” Banerjee said. “That’s fine if you’re looking for something in front of you, but once you get inside the human body it has some shortcomings. The need is to look sideways and backwards.”
For years, there was no solution to this problem until Banerjee’s serendipitous collaboration with Liang led to an idea, followed by an optical design by Liang that led to a proof-of-concept device. The technology is now evolving rapidly toward a completely new and highly affordable method of imaging in medicine.
“It’s been wonderful to work with Banerjee and Liang on this project,” said Amy Phillips, TLA licensing manager for the College of Optical Sciences. TLA provided two rounds of funding via its Asset Development Program to help Banerjee and his team put together the first prototype.
Using a life-size model of a colon as the “test bed” and having trained physicians use the system, detection rates leaped from 59 percent using a standard colonoscope to 90 percent using the dual view imaging probe. A second improved prototype funded by the National Cancer Institute increased average polyp detection to 98 percent.
“That’s when I knew that this must find a way to market,” Phillips said, “and Omniscient is well-positioned to make that happen.”
“The funds from TLA, along with a contribution from a private research grant, were very useful at an early stage because they helped demonstrate the proof of concept,” Banerjee said.
According to Banerjee, success is not just about the technology. It’s about having the right team of experts and advisers.
“It can be a bumpy ride and things don’t always go to plan,” he said. “But when you have the right people on board, you learn valuable lessons and keep moving forwards. I’ve had a very good experience working with TLA. Omniscient has continued to grow and now includes experts and partners in technology, regulatory, marketing, business strategy and finance. I know help is available from Tech Launch if I need it.”
By Paul Tumarkin
*Source: The University of Arizona